Parallax Volatility Advisers
ABUS icon

Parallax Volatility Advisers’s Arbutus Biopharma ABUS Stock Holding History

Parallax Volatility Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200,528
Closed -$383K – 2827
2022
Q3 		$383K Buy
200,528
+176
+0.1% +$414 ﹤0.01% 2077
2022
Q2 		$543K Sell
200,352
-54
-0% -$138 ﹤0.01% 1882
2022
Q1 		$597K Buy
200,406
+48,705
+32% +$149K ﹤0.01% 1851
2021
Q4 		$590K Buy
151,701
+136,070
+871% +$529K ﹤0.01% 2107
2021
Q3 		$67K Buy
+15,631
New +$52.1K ﹤0.01% 2670
2019
Q1 		– Sell
-7,966
Closed -$31K – 2687
2018
Q4 		$31K Buy
+7,966
New +$39.2K ﹤0.01% 2325

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Parallax Volatility Advisers's ABUS Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 200,528 shares — an estimated $383K sold.

Parallax Volatility Advisers first reported a position in ABUS in Q4 2018 and held it in 6 quarters. The position peaked at $597K in Q1 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 200,528 Arbutus Biopharma shares in Q4 2022, an estimated $383K.
  • Parallax Volatility Advisers first reported a position in Arbutus Biopharma in Q4 2018 and held it in 6 quarters.
  • Parallax Volatility Advisers's Arbutus Biopharma position peaked at $597K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.